LA
JOLLA, Calif., Sept. 3,
2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica")
(Nasdaq: CALC), a clinical-stage biopharmaceutical company focused
on developing novel calcium release-activated calcium (CRAC)
channel inhibition therapies for acute and chronic inflammatory and
immunologic illnesses, today announced that Rachel Leheny, Ph.D., Chief Executive Officer,
will participate in a presentation at the H.C. Wainwright
26th Annual Global Investment Conference on Monday, September 9, 2024, at 7:00 a.m. ET/ 4:00 a.m.
PT.
A live webcast of the presentation can be accessed in the
"Upcoming Events" section of CalciMedica's IR website at
https://ir.calcimedica.com/. A replay of the webcast will be
archived on the Company's website for 90 days.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic
diseases. CalciMedica's proprietary technology targets
the inhibition of CRAC channels to modulate the immune response and
protect against tissue cell injury, with the potential to provide
therapeutic benefits in life-threatening inflammatory and
immunologic diseases for which there are currently no approved
therapies. CalciMedica's lead product candidate Auxora™
has demonstrated positive and consistent clinical results in
multiple completed efficacy clinical
trials. CalciMedica has announced topline data for a
Phase 2b trial (called CARPO
– NCT04681066) in patients with AP with SIRS and completed a
Phase 2 trial (called CARDEA – NCT04345614) in patients with
COVID pneumonia. The Company is currently conducting a Phase 2
trial (called KOURAGE – NCT06374797) in patients with AKI with
associated AHRF with data expected in 2025 and continuing to
support the ongoing Phase 1/2 trial (called CRSPA
– NCT04195347) in patients with AIPT with data expected in
2025. CalciMedica was founded by scientists from Torrey
Pines Therapeutics and the Harvard CBR Institute for
Biomedical Research, and is headquartered in La Jolla,
CA. For more information, please
visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-present-at-the-hc-wainwright-26th-annual-global-investment-conference-302234592.html
SOURCE CalciMedica, Inc.
